A Population-based Cohort study to evaluate the treatment compliance with DOACs (Apixaban, Dabigatran, Edoxaban and Rivaroxaban) in patients with non-valvular atrial fibrillation
Latest Information Update: 06 Sep 2019
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Cardiovascular disorders; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Sep 2019 New trial record